All In Biotech

Drug Trial Radar · NCT05104853

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jan 25, 2022

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • CNP-104Drug

    CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.

  • PlaceboDrug

    CNP-104 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: through Study Completion, an average of 720 Days
  2. Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis).Time frame: through Study Completion, an average of 720 Days
  3. Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ)Time frame: through CNP-Dosing Period, an average of 15 Days

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Southern California Research Center

    Coronado, California

  • OM Research

    Lancaster, California

  • University of California Davis Health

    Sacramento, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • University of Florida - Hepatology Research

    Gainesville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Florida Research Institute

    Lakewood Rch, Florida

  • GI PROS Research

    Naples, Florida

  • Cleveland Clinic - Florida

    Weston, Florida

  • Digestive Healthcare of Georgia

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Texas Liver Institute

    San Antonio, Texas

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.